cholesterol-lowering agents

出典: meddic

specific agents

UpToDate Contents

全文を閲覧するには購読必要です。 To read the full text you will need to subscribe.


  • Differential Effects of Atorvastatin and Pitavastatin on Inflammation, Insulin Resistance, and the Carotid Intima-Media Thickness in Patients with Dyslipidemia.
  • Nakagomi A1, Shibui T, Kohashi K, Kosugi M, Kusama Y, Atarashi H, Shimizu W.
  • Journal of atherosclerosis and thrombosis.J Atheroscler Thromb.2015 Jun 17. [Epub ahead of print]
  • AIMS: 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors (statins) have multiple pleiotropic effects, such as anti-inflammatory and vascular endothelium protection, that are independent of their low-density-lipoprotein (LDL) cholesterol lowering effects. However, whether different statins ex
  • PMID 26084792
  • Benzotriazole: An overview on its versatile biological behavior.
  • Briguglio I1, Piras S1, Corona P1, Gavini E1, Nieddu M1, Boatto G1, Carta A2.
  • European journal of medicinal chemistry.Eur J Med Chem.2015 Jun 5;97:612-648. doi: 10.1016/j.ejmech.2014.09.089. Epub 2014 Sep 30.
  • Discovered in late 1960, azoles are heterocyclic compounds class which constitute the largest group of available antifungal drugs. Particularly, the imidazole ring is the chemical component that confers activity to azoles. Triazoles are obtained by a slight modification of this ring and similar or
  • PMID 25293580
  • Coenzyme Q10 remarkably improves the bio-energetic function of rat liver mitochondria treated with statins.
  • Mohammadi-Bardbori A1, Najibi A2, Amirzadegan N2, Gharibi R2, Dashti A2, Omidi M2, Saeedi A2, Ghafarian-Bahreman A2, Niknahad H3.
  • European journal of pharmacology.Eur J Pharmacol.2015 May 22;762:270-274. doi: 10.1016/j.ejphar.2015.05.041. [Epub ahead of print]
  • CoQ10 shares a biosynthetic pathway with cholesterol therefore it can be a potential target of the widely available lipid-lowering agents such as statins. Statins are the most widely prescribed cholesterol-lowering drugs with the ability to inhibit HMG-CoA (3-hydroxy-3-methylglutaryl-coenzyme A) red
  • PMID 26007644


  • Standard-Dose Statin Therapy Provides Incremental Clinical Benefits in Normocholesterolemic Diabetic Patients
  • KOJIMA Sunao,SAKAMOTO Tomohiro,OGAWA Hisao,KITAGAWA Akira,MATSUI Kunihiko,SHIMOMURA Hideki,KIMURA Kazuo,OGATA Yasuhiro,SAKAINO Naritsugu,the Multicenter Study for Aggressive Lipid-lowering Strategy by HMG-CoA Reductase Inhibitors MUSASHI investigators
  • Circulation journal : official journal of the Japanese Circulation Society 74(4), 779-785, 2010-03-25
  • … A total number of 1,016 CHD patients (301 patients with type 2 diabetes mellitus [DM] and 715 non-DM patients) with serum total cholesterol levels of 180-240 mg/dl were randomly divided into non-statin and statin treatments. … Serum low-density lipoprotein (LDL)-cholesterol levels were equally decreased after statin treatment in the 2 groups. … Conclusions: Standard-dose statin therapy provides incremental clinical benefits in DM patients with normal cholesterol levels compared with non-DM patients. …
  • NAID 10026472717
  • Hypolipidemic Effects of Sophora flavescens and Its Constituents in Poloxamer 407-Induced Hyperlipidemic and Cholesterol-Fed Rats(Pharmacognosy)
  • KIM Hyun Young,JEONG Da Mi,JUNG Hee Jin,JUNG Yu Jung,YOKOZAWA Takako,CHOI Jae Sue
  • Biological & pharmaceutical bulletin 31(1), 73-78, 2008-01-01
  • … In this study, we investigated the hypolipidemic effects of Sophora flavescens in poloxamer 407-induced hyperlipidemic and cholesterol-fed rats. … Serum lipid levels such as total cholesterol (TC), triglycerides (TG), and low-density lipoprotein-cholesterol (LDL-C) were markedly elevated in the poloxamer 407-induced hyperlipidemic control rats, while lipid levels were significantly decreased in the rats administered the MeOH extract or 4 fractions of S. …
  • NAID 110006569977


Omudhome Ogbru, PharmD. Dr. Ogbru received his Doctorate in Pharmacy from the University of the Pacific School of Pharmacy in 1995. He completed a Pharmacy Practice Residency at the University of Arizona/University Medical Center in ...






  • n.
  • 代行者、代理人。代理業者
  • 政府職員、官吏
  • ある後位をする人、ある作用をするもの。動員、動力因、作用因。(文法)動作主。科学的変化を起こさせるもの、薬品、~剤。病原体
agonistagonisticattorneydelegatedrugetiologic agentfomesfomitesmediatorpathogenpathogenicpharmaceutical preparationvectorvehicle

WordNet   license wordnet

「a substance that exerts some force or effect」

WordNet   license wordnet

「a businessman who buys or sells for another in exchange for a commission」
factor, broker

WordNet   license wordnet

「any agent or representative of a federal agency or bureau」
federal agent

WordNet   license wordnet

「a representative who acts on behalf of other persons or organizations」

WordNet   license wordnet

「an active and efficient cause; capable of producing a certain effect; "their research uncovered new disease agents"」

PrepTutorEJDIC   license prepejdic

「『代理人』;周旋人 / 働き(作用)を起こすもの;作用物,薬剤 / (政府機関,特にFBI,CIAなどの)部員,機関員」



  • n.

WordNet   license wordnet

「the act of causing something to move to a lower level」
letting down

WordNet   license wordnet

「the act of causing to become less」

PrepTutorEJDIC   license prepejdic


PrepTutorEJDIC   license prepejdic

「(空模様が)険悪な,荒れ模様の / しかめっつらの,(顔つきが)不機嫌な」


  [★] コレステロール

WordNet   license wordnet

「an animal sterol that is normally synthesized by the liver; the most abundant steroid in animal tissues」

PrepTutorEJDIC   license prepejdic